tbuckley/cabot-search huggingface dataset:
The value of breast cancer survivorship care plans: Results from a community survey.
Authors: Stephanie L. Graff, Peg Wisner, Gina Shay-Zapien, Michaela Logan, David Moorman
Journal: Journal of Clinical Oncology (2018)

e22125 Background: Survivorship care plans (SCP) are an integral part of National Accreditation Program for Breast Centers and the Commission on Cancer accreditation, both recommending SCPs for at least 50% of eligible patients (pts) in 2017. In our community-based program, SCPs are provided and reviewed during a follow-up appointment (appt). SCPs are created using proprietary Sarah Cannon Research Institute iNavigate software, Journey Forward, and the ASCO treatment summary. All formats include the same key elements. A written copy of the pt’s SCP is provided to the pt, full care team, and included in the medical record. Methods: Breast program leaders wrote a survey to assess recall of the SCP. We identified 130 breast cancer pts from 2 hospitals who completed a SCP appt from January 2016 to October 2017 without evidence of recurrence. Results: 130 pts were identified, and 71 (54.6%) returned a survey. Though 83% (95% CI: 72%, 91%) of the respondents recalled having a SCP appt, less found it helpful or remembered keeping a copy of their SCP. Table 1 summarizes results. Conclusions: Ideally all patients should have a valuable SCP experience. We need to identify barriers that prevent patients from experiencing the full benefits of a SCP and optimize this vital tool for patient communication and continued care Table 1. Yes No Not applicable Do not recall Did you have a SCP appt? 59 (83.1%) (95% CI 72.3, 91.0) 3 (4.2%) - 9 (12.7%) Did you find appt helpful? 53 (74.6%) (95% CI 62.9, 84.2) 3 (4.2%) - 15 (21.1%) Did you receive a copy of your SCP? 42 (59.2%) (95% CI 46.8, 70.7) 13 (18.3%) - 16 (22.5%) Was contact information included? 43 (60.6%) 13 (18.3%) - 15 (21.1%) Was your cancer diagnosis and stage included? 50 (70.4%) 11 (15.5%) - 10 (14.1%) Information on your surgery? 49 (69.0%) 9 (12.7%) 4 (5.6%) 9 (12.7%) Information on your medical treatment (chemo and/or pills?) 50 (70.4%) 8 (11.3%) 7 (9.9%) 6 (8.5%) Information on your radiation? 34 (47.9%) 10 (14.1%) 20 (28.2%) 7 (9.9%) Recommendations for follow up appts? 51 (71.8%) 9 (12.7%) 1 (1.4%) 10 (14.1%) Recommendations for follow up imaging? 52 (73.2%) 7 (9.9%) 4 (5.6%) 8 (11.3%) Information on long term side effects? 33 (46.5%) 20 (28.2%) - 18 (25.4%) Did you keep a copy of SCP? 37 (52.1%) (95% CI 39.9, 64.1) 14 (19.7%) - 20 (28.2%)
Safety and efficacy of extended bevacizumab (BEV) therapy in elderly (≥70 years) patients (pts) treated for newly diagnosed ovarian cancer (OC) in the international ROSiA study.
Authors: Frédéric Selle, Nicoletta Colombo, Jacob Korach, Cesar Mendiola, Nicolas Martin, Stephen Robb, Amit M. Oza
Journal: Journal of Clinical Oncology (2016)

5535 Background: The single-arm ROSiA safety study explored an extended duration of front-line BEV for OC. We report exploratory analyses of safety and efficacy according to age. Methods: After primary debulking surgery, pts with FIGO stage IIB‒IV or grade 3 stage I‒IIA OC received 4‒8 cycles of paclitaxel (weekly or q3w), carboplatin AUC 5–6 q3w, and BEV 15 (or 7.5) mg/kg q3w, followed by single-agent BEV for up to 24 mo (or longer at the investigator’s discretion) or until progression if earlier. The primary endpoint was safety; progression-free survival (PFS; by RECIST/symptomatic deterioration) was a secondary endpoint. Results: Of 1021 pts enrolled, 121 (12%) were aged ≥ 70 years and 44 (4%) were ≥ 75 years. Compared with pts < 70 years, the elderly subgroup included more pts with hypertension (HTN) at baseline (70% vs 28%, respectively), stage IIIB–IV disease (84% vs 76%), and ECOG performance status ≥ 1 (39% vs 29%). A 15 mg/kg BEV dose was chosen in 83% vs 90% of pts aged ≥ 70 vs < 70 years, respectively. The median BEV duration was 14.6 vs 15.9 mo, respectively; BEV was continued for > 15 mo in 49% vs 53% and for > 24 mo in 21% vs 30%. BEV was discontinued for reasons other than disease progression in 53% vs 41% (22% vs 17% for unacceptable toxicity). There was no excess of fatal AEs, including thromboembolic events (TEs), in older vs younger pts. Conclusions: BEV-treated pts aged ≥ 70 years had higher incidences of low-grade diarrhea and grade ≥ 3 HTN, TE and asthenia than those < 70 years, but no other relevant increase in toxicity. Median PFS of ~2 years is similar to that in younger pts despite the worse prognosis. Older age should not preclude use of BEV in carefully selected OC pts aged ≥ 70 years. Given the higher background HTN prevalence, elderly pts should be monitored more closely while receiving BEV. Clinical trial information: NCT01239732.Parameter < 70 years (n = 900) ≥ 70 years (n = 121) Any AE, % HTN 54 60 Neutropenia 49 50 Anemia 32 44 Fatigue 37 36 Diarrhea 25 35 Epistaxis 30 24 Asthenia 12 22 Grade ≥ 3 AE, % 65 80 HTN 22 41 TE* 2 7 Asthenia 1 6 Proteinuria 4 2 GI perforation 1 3 Median PFS, mo (95% CI) 25.6 (23.7‒28.4) 23.7 (18.6‒27.9) RECIST response rate, % (95% CI) 74 (69‒79) 64 (50‒76) *Wide group of AE terms; AE = adverse event
A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Authors: Ulka N. Vaishampayan, David F. McDermott, Marc Ryan Matrana, Sun Young Rha, Amado J. Zurita, Thai Huu Ho, Bhumsuk Keam, Jae-Lyun Lee, Richard Wayne Joseph, Sarah Ali, Walter Michael Stadler, Naomi B. Haas, Srinath Sundararajan, Se Hoon Park, Rex B. Mowat, Joel Picus, Arkadiusz Z. Dudek, Yousef Zakharia, Lu Gan, Michael B. Atkins
Journal: Journal of Clinical Oncology (2018)

4510 Background: X4P-001 is an oral, selective, allosteric inhibitor of the chemokine receptor CXCR4, which is a promising novel target in renal cell carcinoma (RCC). X4P-001 in combination with the tyrosine kinase inhibitor axitinib demonstrated greater than additive anti-tumor activity in xenograft models mediated by decreased myeloid-derived suppressor cell trafficking and reduced proangiogenic signaling. Methods: This is a Phase (Ph) 1/2 trial in patients (pts) with advanced clear cell RCC who have failed at least one prior therapy. The safety, tolerability, and recommended Ph 2 dose (RP2D) of X4P-001 in combination with axitinib was established in Ph 1. Here we report results for preliminary efficacy in both the Ph1 dose escalation cohorts and the Ph 2 expansion cohort of pts treated at the RP2D. Results: The Ph 1 portion of the study is completed and established the combination therapy to be safe and tolerable at the RP2D of 400 mg QD X4P-001 + 5 mg BID axitinib. As of 01 January 2018, data are available for 10 pts in Ph 1 and 41 pts in Ph 2 treated at the daily 400 mg dose (either 200 mg BID or 400 mg QD) of X4P-001 + 5 mg BID axitinib. The median age was 64 years (range 41-87). Patients had received a median of 2 prior lines of systemic therapy (1 line: 29%; ≥ 2 lines: 71%). Seven pts (13.7%) were discontinued from the study due to adverse events (AEs) regardless of relationship. Of the 22 clinically evaluable pts, the objective response rate was 31.8% (1 CR; 6 PR) and the disease control rate was 86.4%. Median duration on treatment was 24 weeks (range 2 - 84). The most common (≥ 10%) treatment-related AEs of any grade were diarrhea, fatigue, hypertension, decreased appetite, dysphonia, nausea, blood creatinine increased, dry eye, headache, and vomiting. Hypertension was the only treatment-related AE (≥ Grade 3) to occur in > 5% of pts (9.8%) and the only serious AE to occur in more than one pt (3.9%). Conclusions: Preliminary results from the study demonstrate that X4P-001 + axitinib is clinically active in pts with advanced clear cell RCC and well tolerated with a manageable safety profile. Enrollment in the Ph 2 portion is near-completion and updated study results will be reported. Clinical trial information: NCT02667886.
PMMC deltopectoral (DP) Composite sandwich flap: A innovative locoregional solution for huge complex defects after head and neck cancer surgery.
Authors: Jeetendra Paryani
Journal: Journal of Clinical Oncology (2018)

e18003 Background: Oral cavity Cancer is the most common malignancy in India. It is not very uncommon for cancer to present at advanced stage. Resection of such lesion may result in large complex defects. Reconstruction of such defects could be done by loco Regional Flaps or combination of or alone by free flaps. We describe the technique of composite PMMC –DeltoPectoral (DP) Flap reconstruction for reconstruction of such defects. Methods: The patients with locally advanced oral cavity cancer from the period of September 2015 to January 2016 were operated & reconstructed using this technique in our institute. Standard Techniques used for resection & neck dissection. PMMC Flaps were used for coverage on the mucosal side of the defect and DP flap was used to cover the skin loss and both flaps sutured to each other at the junction. . Postoperative outcome and final cosmesis was evaluated . Results: 18 patients were reconstructed using this technique. All were males. Only one patients suffered major Flap necrosis. But patient recovered and reconstructed using the same flap. Two patients developed minor orocutaneous fistula which recovered on conservative management. The cosmesis of the patients was good . Conclusions: Large complex defects involving both oral cavity and skin posses a unique reconstructive challenge.This technique represents an innovative solution in reconstruction oral cavity defects with large skin loss.This flaps provide inner PMMC in oral lesion & DP provides outer skin coverage. The use both the flaps which are sutured at the junction represents a new answer to difficult question of reconstruction of large defects. Also that solution does not require complex micro vessel anastomosis or significant donor site morbidity. . We have modified the technique of flap in such a way that edge of flap is sutured to neck dissection wound. This avoids the need for second stage for divison of defect resulting in shortening of traditionally long hospital stay required for standard deltopectoral flaps.With continuing use of such composite flaps we plan to refine better technique & modifications to improve outcomes and cosmesis in patients requiring large reconstructions
PD-1 blockade in metastatic melanoma (MEL): The University of Pittsburgh experience.
Authors: Diwakar Davar, Ling Tian, Fei Ding, Cindy Sander, Ahmad A. Tarhini, John M. Kirkwood
Journal: Journal of Clinical Oncology (2016)

e21031 Background: PD-1 inhibitors have reported response rates of 34-40% in patients (pts) with advanced MEL. Landmark 1- and 2- year survival rates with Nivolumab (Nivo), Pembrolizumab (Pembro) and Ipilimumab/Nivolumab are 63%/48%, 66%/49% and 74%/pending, respectively. Methods: Clinical and radiological data were collected on 81 pts who received Nivo or Pembro at a single institution to treat advanced cutaneous and unknown primary melanoma. Baseline characteristics at the time of initial therapy and outcome data including best/current response, progression-free (PFS) and 1- year overall survival (OS) were collected. Response calculated using RECIST 1.1. Influence of baseline characteristics on treatment outcomes assessed using log-rank test. Results: BRAF and NRAS mutations were detected in 33.3% and 17.3% respectively. 61 patients were evaluable for response. Complete and partial response (CR/PR) rates were 9.8% and 31.1% for an overall response rate (ORR) of 41.0%. Progression was documented in 35 (57.4%) of pts. Median progression-free (PFS) and overall survival (OS) was 3.2 and 7.5 months in progressors. Conclusions: In 81 pts with advanced MEL, ORR and 1-year OS rate to PD-1 blockade was 41.0% and 52.9%. ORR was similar regardless of line of therapy or receipt of prior CTLA-4 therapy. Median PFS and OS was 3.2 and 7.5 months in progressors, but has not been reached in responding pts. Pts with BRAF mutations and CNS+liver metastases had poorer PFS. N Median PFS (mths) (CI) Log-rank p-value Median OS (mths) (CI) Log-rank p-value Cutaneous 60 (74.0%) 6.6 (4.2-12.8) Not reached Unknown primary 21 (26.0%) CNS/Liver met 0.059 0.002 Both 7 (8.6%) 2.1 (0.13-.) 2.8 (0.13-.) CNS 19 (23.5%) 12.8 (2.14-.) Not reached Liver 12 (14.8%) 8.3 (3.2-.) Not reached Other mets 43 (53.1) 6.6 (4.1-.) Not reached Line of Therapy 0.642 0.522 1st line 28 (34.6%) 5.2 (2.7-.) Not reached > = 2nd line 53 (65.4%) 6.6 (4.1-.) Not reached Prior CTLA-4 therapy 0.637 0.614 Yes 40 (49.4%) 8.3 (4.1-.) 11.9 (7.46-.) No 41 (50.6%) 4.9 (3.9-.) Not reached Mutation Status 0.004 0.008 BRAF mutated 27 (33.3%) 4.0 (2.1-4.9) 7.6 (3.6-11.0) NRAS mutated 14 (17.3%) 6.6 (2.8-.) Not reached BRAF/NRAS WT 26 (32.1%) Not reached Not reached Progressors 35 (57.4%) 3.2 (2.1-4.1) 7.5 (3.6-8.1)
P01.152 Evaluation of Factor V Leiden variant as risk a factor for venous thromboembolism in glioblastoma patients
Authors: M Heenkenda, M Łysiak, L Åkesson, P Milos, M Mudaisi, C Bratthäll, M Strandeus, P Söderkvist, S Uppugunduri, A Osman, A Malmström
Journal: Neuro-Oncology (2018)

Venous thromboembolic events (VTE) are common complications in patients with glioblastoma (GBM). Factor V Leiden (FVL) polymorphism (rs6025, c.1601 G>A) is a known risk factor for VTE, evaluated in cancer associated thrombosis (CAT) in different tumor types. Little is known about the role of this variant in development of CAT in patients with GBM. A cohort of 116 GBM patients (73 males and 43 females) all treated with concomitant temozolomide and radiotherapy, were genotyped for FVL using PCR- pyrosequencing. Of the cohort, 40 patients were diagnosed with and 76 without VTE. Allele frequencies of respective variant were also compared with data from the SweGen Variant Frequency Browser (https://swegen-exac.nbis.se/). Statistical analyses in regard to VTE and its association with FVL and prognostic factors were performed. The variant A/G of FVL was carried by 17 (15%) of the patients and 99 (85%) were wild type, G/G. Chi2 test including the prognostic factors age, type of surgery, gender and blood group showed that these were evenly distributed between those with G/G and A/G, except for blood group in relation to FVL variant, which showed a borderline significance (p=0.07). Among the patients having blood group 0, 32% (n= 32) were G/G and 59% (n= 10) were A/G. Statistical tests did not reveal any correlation between blood group and FVL variant. In the logistic regression analysis apart from FVL, age, gender and blood group were included. This showed a significant difference for blood group 0 versus non-0 (A, B or AB) for decreased risk of VTE (P=0.014). There was no significant difference between heterozygous FVL (A/G) versus the G/G genotype in VTE risk (p=0.09). There were no differences in survival in relation to VTE or not or variant of FVL. The FVL AG variant is slightly overrepresented among GBM compared to the normal Swedish population, but does not reach statistical significance, OR 1.63 (0.93–2.84). We examined the influence of FVL variants together with clinical factors in a homogenously treated cohort of GBM patients for the risk to develop a VTE. We confirmed blood group 0 versus non-0 as reducing the VTE risk. For FVL c.1601 G>A variant, the differences between AG vs GG did not reach statistical significance. In our cohort we found a trend towards increased risk of developing GBM for the A/G variant. We plan to further study other factors involved in coagulation for their potential role in GBM patients.
Oncogenic receptor tyrosine kinase (RTK) translocations in a subset of quadruple wild-type gastrointestinal stromal tumors (GIST).
Authors: Michael C. Heinrich, Guhyun Kang, Andrea Warrick, Christopher L. Corless, Carol Beadling
Journal: Journal of Clinical Oncology (2016)

11012 Background: The vast majority of GIST have activating oncogenic mutations of KIT (75%) or PDGFRA (15%). A proportion of the remaining 10% of GIST have mutations involving the RAS-MAPK pathway (gain-of-function RAS/ BRAF mutations or loss of function NF1 mutations). GIST lacking KIT, PDGFRA, or RAS-MAPK pathway mutations often lack a functional succinate dehydrogenase (SDH) complex, caused by mutation or epimutation of one of the four SDH subunit genes. GIST without KIT, PDGFRA RAS-MAPK, or SDH complex mutation/dysfunction have been designated as
A mutation of the human EPHB2 gene leads to a major platelet functional defect
Authors: Eliane Berrou, Christelle Soukaseum, Rémi Favier, Frédéric Adam, Ziane Elaib, Alexandre Kauskot, Jean-Claude Bordet, Paola Ballerini, Stephane Loyau, Miao Feng, Karine Dias, Abbas Muheidli, Stephane Girault, Alan T. Nurden, Ernest Turro, Willem H. Ouwehand, Cécile V. Denis, Martine Jandrot-Perrus, Jean-Philippe Rosa, Paquita Nurden, Marijke Bryckaert
Journal: Blood (2018)
Omacetaxine mepesuccinate for patients with higher-risk MDS and CMML after failure of hypomethylating agents: A phase II clinical trial.
Authors: Gabriela Sanchez-Petitto, Guillermo Garcia-Manero, Nicholas James Short, Kiran Naqvi, Michael Andreeff, Koichi Takahashi, Steven Kornblau, Prithviraj Bose, Zeev Estrov, Marina Konopleva, Ami Patel, Rabiul Islam, Yesid Alvarado, Courtney Denton Dinardo, Hagop M. Kantarjian, Elias Jabbour
Journal: Journal of Clinical Oncology (2018)

7066 Background: Hypomethylating agents (HMAs) are the standard of care for patients (pts) with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML); however, outcomes after HMA failure are poor. We designed a phase II trial to evaluate omacetaxine mepesuccinate (OM) in pts with MDS and CMML after HMA failure. Methods: Eligible pts were > 18 years of age, and had intermediate-1- or higher-risk MDS or CMML by the International Prognostic Scoring System (IPSS) and/or bone marrow (BM) blasts 5-30%, that had not responded to, progressed on, or relapsed after HMA therapy. OM was given at 1.25 mg/m2 SQ every 12 hours for 3 days on a 28-day cycle, until progression or unacceptable toxicity. Primary endpoints were overall response rate (ORR) and overall survival (OS). Results: From 6/2015 to 11/2017, 42 pts were enrolled. Median age was 76 years (range, 61-87); 8 pts (19%) had CMML. 17 pts (40%) had adverse-risk cytogenetics, and 19 pts (45%) had received 2 or more prior therapies. Median BM blasts was 10% (range, 2-20%). The median duration of follow-up was 25 months, and the median number of cycles of OM received was 3 (range, 1-23). The ORR was 33%; 3 pts achieved CRp, 10 achieved CRi and 1 achieved HI with a median number of cycles to best response of 2 (range, 1-9 cycles). Response rates for pts with MDS and CMML were 35% (12/34) and 25% (2/8), respectively. Response rates for pts with diploid and adverse-risk cytogenetics were 58% (7/12) and 24% (4/17), respectively (P = 0.057). Of the 14 responders, 5 remain on study, 6 relapsed, 2 died while in response, and 1 was lost to follow-up. The median OS was 7.5 months, and the 1-year OS rate was 25%. The median RFS was 4.9 months, and the 1-year RFS rate was 14%. Two pts are alive with ongoing response after ≥2 years of treatment; both had MDS with diploid cytogenetics and a RUNX1 mutation. Overall, the treatment was well-tolerated. Among 39 pts who received ≥2 cycles of OM, 8 (21%) required dose reduction. The 30-day and 60-day mortality rates were 10% and 14%, respectively. Conclusions: In patients with MDS and CMML with prior HMA failure, OM resulted in an ORR of 33% with a median OS of 7.5 months. Some pts had long-term responses to OM. Clinical trial information: NCT02159872.
Chemotherapy after immunotherapy failure in patients with advanced gastrointestinal tumors
Authors: I. Baraibar Argota, P. Martin Romano, M.F. Sanmamed, M. Rodríguez Ruiz, I. Melero, L. Resano, A. Chopitea Ortega, M. Ponz-Sarvisé, E. Castanon Alvarez
Journal: Annals of Oncology (2018)

Background: First line therapies usually induce the longest progression free survival (PFS) in metastatic gastrointestinal cancers (GIC) as compared to subsequent lines of treatment. However, immunotherapy (IT) due to its mechanisms of action could influence sensitivity to conventional cancer therapy (CCT) after progression to IT and thereby, influence both tumor growth rate (TGR) and PFS. We have studied TGR and PFS before and after participation in phase I IT trials. Methods: Patients enrolled in Phase I IT trials run at our institution between Jan 2012 and Sept 2017 with GIC including colorectal cancer (CRC), esophagogastric cancer (EGC) and pancreatic cancer (PC), treated with at least one line of CCT before and after IT failure were included in the analysis. Baseline characteristics were recorded. A ratio of PFS after/before IT (PFSaft/befIT) over 1.2 was considered clinically significant. TGR was calculated based on the formulas: TGR = 100 (exp(TG)−1), TG = 3 Log(Dt/D0)/t. Correlation between PFSaft/befIT and GRIm score was evaluated. Results: Nineteen patients met the inclusion criteria (17 CRC pt, 1 EGC pt, 1 PC pt). Table 1 shows baseline characteristics. Median PFS befIT and aftIT were 4.4 and 3.1 months, respectively. Seven of 19 patients presented a PFSaft/befIT rate over 1.2. TGRbef and TGRaft data were available from 9 patients; 1 patient (CRC) presented a decrease in TGR greater than 15% after IT failure. Patients experiencing a ratio of PFSaft/befIT over 1.2 tended to score better in GRIm prognostic classification (0-1: 100% vs 66%, (p = 0.09)).Table: 61PCharacteristicsN = 19Male11Median (M) age at diagnosis (range)54 (34-79)M lines prior to IT (range)2 (1-5)Presence of liver disease (pre/IT/post)9/10/13CCT class (pre/post IT) Platinum derivatives Other alkylating agents (a) Antimetabolites Topoisomerase inhibitors (i) Antimicrotubules a Antiangiogenic a Signal transduction i Immunotherapy Others4/8 0/1 15/11 12/4 1/1 11/9 2/2 4/0 3/3Combined/monotherapy during IT11/8MSI/MSS/unknown2/7/10 Open table in a new tab Conclusions: Our data suggest a better outcome on ensuing systemic therapies after IT. Further prospective investigations are needed to select the subset of patients who are more prone to a re-sensitization to CCT and to understand the mechanisms underlying. Legal entity responsible for the study: Clínica Universidad de Navarra. Funding: Has not received any funding. Disclosure: I. Melero: Advisor: BMS, Roche, AstraZeneca, Genmab, Alligator, Tusk, Bioncotech, Merck-Serono. All other authors have declared no conflicts of interest.
Patenting Foundational Technologies: Lessons From CRISPR and Other Core Biotechnologies
Authors: Oliver Feeney, Julian Cockbain, Michael Morrison, Lisa Diependaele, Kristof Van Assche, Sigrid Sterckx
Journal: The American Journal of Bioethics (2018)

In 2012, a new and promising gene manipulation technique, CRISPR-Cas9, was announced that seems likely to be a foundational technique in health care and agriculture. However, patents have been granted. As with other technological developments, there are concerns of social justice regarding inequalities in access. Given the technologies' "foundational" nature and societal impact, it is vital for such concerns to be translated into workable recommendations for policymakers and legislators. Colin Farrelly has proposed a moral justification for the use of patents to speed up the arrival of technology by encouraging innovation and investment. While sympathetic to his argument, this article highlights a number of problems. By examining the role of patents in CRISPR and in two previous foundational technologies, we make some recommendations for realistic and workable guidelines for patenting and licensing.
Common Phenotype in Patients With Mitral Valve Prolapse Who Experienced Sudden Cardiac Death
Authors: Jérôme Hourdain, Marie Annick Clavel, Jean-Claude Deharo, Samuel Asirvatham, Jean François Avierinos, Gilbert Habib, Frederic Franceschi, Vincent Probst, Nicolas Sadoul, Raphael Martins, Christophe Leclercq, Michel Chauvin, Jean Luc Pasquie, Philippe Maury, Gabriel Laurent, Michael Ackerman, David O. Hodge, Maurice Enriquez-Sarano
Journal: Circulation (2018)

ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.